Grace Baek, PharmD, BCOP

This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.

Opportunities for further optimization of CML management remain.

New agents can offer a more tailored approach to therapy selection.

Melanoma is responsible for 80% of skin cancer deaths.

New therapeutics for prostate cancer must continue to be assessed for comparative safety and efficacy, as well as accessibility for patients.